| 陈梦园,潘雅文,林苏进,程志清,潘录录,周珊珊,刘晓蝶,支英豪.条达枢机法治疗肝气郁滞型卒中后抑郁的临床疗效观察[J].浙江中西医结合杂志,2025,35(3): |
| 条达枢机法治疗肝气郁滞型卒中后抑郁的临床疗效观察 |
| Clinical Observation of Tiaoda-Shuji Method on 60 Cases of Post-stroke Depression of Liver Qi Stagnation Type. |
| 投稿时间：2024-07-27 修订日期：2024-12-19 |
| DOI： |
| 中文关键词: 条达枢机法 解郁方 卒中后抑郁。 |
| 英文关键词:Tiaoda-Shuji Method Jieyu prescription post-stroke depression. |
| 基金项目:浙江省中医药创新团队建设项目(浙卫发[2023]31号)；浙江中医药大学科研专项资助项目(2023FSYYZZ18);温州市科技局项目(Y2023253)。 |
|
| 摘要点击次数: 422 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的:观察条达枢机法治疗肝气郁滞型卒中后抑郁症的临床疗效。方法:纳入了符合研究标准的卒中后抑郁病人共71例,包括观察组41例和对照组30例,两组均予脑卒中常规方法治疗和其他对症治疗。对照组予抗抑郁西药(盐酸帕罗西汀片)口服治疗；观察组在西药基础上联合中药解郁方口服治疗,共8周。把两组病人治疗前后的中医证候积分表格、17项汉密尔顿抑郁表格(Hamilton Depression Scale,HAMD-17)、抑郁自评表格(Self-rating depression scale,SDS)及简式Fugl-Meyer运动功能表格(Fugl-Meyer Assessment Scale,FMA)进行比较分析。结果:在总有效率对比上,观察组高于对照组,有统计学意义(P＜0.05)。两组患者接受8周治疗后,中医证候积分、HAMD、SDS及FMA均有降低,但观察组降低更显著,且中度抑郁组的HAMD及SDS评分较轻度抑郁组降低更为明显,差异均具有统计学意义(P＜0.05)。结论:具有条达枢机作用的解郁方能够有效改善肝气郁滞型卒中后抑郁患者的抑郁程度及临床症状,同时能改进PSD患者的运动功能,具有良好的临床疗效。 |
| 英文摘要: |
| Objective: To observe the clinical effect of PSD with liver-qi stagnation in Tiaoda-Shuji. Methods: 71 PSD patients were divided into 2 groups (41 and 30 patients, respectively). Both groups received basic symptomatic treatment. The control group was given paroxetine hydrochloride tablets; the observation one was western medicine combined with Jieyu prescription orally for 8 weeks. The differences of TCM symptom,HAMD-17, SDS and FMA in PSD patients before and after treatment were compared. Results: The total effective rate of the observation group was better than the control one, with statistical significance (P<0.05). After 8 weeks, four scales were decreased in both groups, but the observation group was more significant, and the HAMD and SDS in the moderate depression group were more significantly decreased than the mild depression group, with statistical significance (P<0.05). Conclusion: Jieyu prescription of tiaoda-shuji can effectively improve the symptoms of PSD with liver-qi depression, have a good clinical efficacy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
